Logo.png
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
August 17, 2021 07:45 ET | Protagenic Therapeutics, Inc.
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Logo.png
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
July 23, 2021 16:21 ET | Protagenic Therapeutics, Inc.
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Logo.png
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
July 06, 2021 06:17 ET | Protagenic Therapeutics, Inc.
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Logo.png
Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
June 16, 2021 09:15 ET | Protagenic Therapeutics, Inc.
NEW YORK , June 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a bioharmaceutical company focused on developing drug product candidates to treat stress-related neurologic...
Logo.png
Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq
April 29, 2021 15:06 ET | Protagenic Therapeutics, Inc.
New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a...
Logo.png
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering
April 26, 2021 20:58 ET | Protagenic Therapeutics, Inc.
New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a...
Logo.png
Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial
December 16, 2020 09:15 ET | Protagenic Therapeutics, Inc.
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...
Logo.png
Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing
September 08, 2020 12:10 ET | Protagenic Therapeutics, Inc.
Capital to be Used to Complete IND Filing and Commence Phase I/II Clinical Trial for Lead Clinical Compound PT00114 NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc....
Three High Profile Publications Support the Potential of Protagenic Therapeutics’s Synthetic TCAP to Treat Stress-Related Psychological Disorders
June 11, 2018 10:15 ET | Protagenic Therapeutics, Inc.
Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology NEW YORK,...